ホーム › COPD › テキサス › Dallas

Dallas、TXにおけるCOPDの臨床試験

Dallasとその周辺地域（約30マイル以内）の拠点で、COPDに関する12件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト（英語）

ここで研究参加者を募集していますか？このページの上部に表示できます — 30日間 $99 →

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

被験者募集中第3相

IntraCare- Site Number : 8400034, Dallas

40歳〜80歳 · 全性別 · 2026/10/01更新 · NCT07190222

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

被験者募集中第3相

Texas Health Presbyterian Hospital Dallas- Site Number : 8400032, Dallas

40歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07190209

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

被験者募集中

University of Texas Southwestern, Dallas

40歳〜80歳 · 全性別 · 2026/09/17更新 · NCT06035120

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

被験者募集中第2相

Research Site, Dallas

40歳以上 · 全性別 · 2026/09/09更新 · NCT07082738

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

被験者募集中第3相

Research Site, Dallas

40歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06883305

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

被験者募集中第2/3相

Alina Clinical Trials, LLC., Dallas

35歳〜80歳 · 全性別 · 2026/08/31更新 · NCT07363694

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

被験者募集中第3相

Research Site, Dallas

40歳〜80歳 · 全性別 · 2026/08/26更新 · NCT06283966

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

被験者募集中第3相

GC2501 Study Site 109, Dallas

18歳〜80歳 · 全性別 · 2026/08/11更新 · NCT07555483

STRIVE Post-Market Registry Study

被験者募集中観察研究

Baylor Scott & White Research Institute, Dallas
University of Texas Southwestern, Dallas

18歳以上 · 全性別 · 2026/08/03更新 · NCT04302272

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

被験者募集中第3相

GSK Investigational Site, Dallas

40歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07177339

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

被験者募集中観察研究

Liver Center of Texas, Dallas

18歳以上 · 全性別 · 2026/07/10更新 · NCT05181826

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

被験者募集中第3相

GSK Investigational Site, Dallas

40歳〜80歳 · 全性別 · 2026/04/09更新 · NCT06961214

他の都市におけるCOPDの試験

Dallasにおける他の研究

ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。